Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 169, Issue 6, Pages 814-823Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.13367
Keywords
deoxycoformycin; cyclophosphamide; small lymphocytic lymphoma; follicular lymphoma; marginal zone lymphoma
Categories
Funding
- NCI NIH HHS [P30 CA008748, P30 CA016672] Funding Source: Medline
Ask authors/readers for more resources
We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 916% attained an overall response and 868% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P=001): 83% [95% confidence interval (CI): 072, 096] for follicular lymphomas, 73% (95% CI: 054, 10) for marginal zone lymphomas and 61% (95% CI: 046, 081) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60years of age.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available